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INTRODUCTION
Non-communicable diseases accounted for 72.3% of deaths globally in 2016 [1] . Ischaemic heart disease and cerebrovascular disease are the highest contributors to this mortality and morbidity [1] . Metabolic disorders such as type 2 diabetes (T2D) and dyslipidaemia are important cardiovascular disease risk factors. In 2017 an estimated 425 million people had diabetes worldwide and the number is projected to increase -disproportionately in low and middle income countries (LMIC) -to 629 million by 2045 [2] .
Dyslipidaemia, which results in atherosclerosis, is the leading risk factor for myocardial infarction [3] and stroke [4] .
Chronic, low-grade, obesity-driven inflammation has been implicated in the aetiology and progression of insulin resistance and T2D [5] . Atherosclerosis results from a chronic inflammatory state mediated by macrophages in the vascular sub-endothelium combined with high levels of lipids in the systemic circulation [6] . Lipids are utilised by and involved in mediation of immune processes; therefore inflammation may influence lipid levels in the circulation [7] . Modulation of these inflammatory processes may delay the development of T2D and atherosclerosis.
Over a billion people are helminth-infected worldwide, predominantly in LMIC [8] . Helminths have coevolved with humans over millions of years so that they survive in the human host but mostly cause only subtle harm. To ensure survival, helminths modify type 2 and regulatory immune responses in the human host [9] . With these immunomodulatory properties, helminths may be able to annul the inflammation that results in metabolic disorders and therefore confer protection [10] . Studies in experimental animals support this hypothesis. Mice infected with Schistosoma mansoni [11] , Nippostrongylus brasiliensis [12] and Litomosoides sigmodontis [13] had decreased insulin resistance and improved glucose tolerance compared to uninfected mice. Infection of mice with S. mansoni cercariae [14] and intra-peritoneal inoculation of S. mansoni eggs [15] resulted in lower blood lipid levels than in uninfected/un-inoculated controls. In mice, S. mansoni infection also reduced development of atherosclerotic lesions [14] and ES-62, a product from the filarial nematode Acanthocheilonema vitae, caused a 60% reduction in aortic atherosclerotic lesions [16] .
In humans, published studies investigating the effect of helminths on metabolic outcomes are few and observational, except for a single trial. In China, history of Schistosoma japonicum infection was associated with lower levels of fasting blood glucose, glycated haemoglobin (HbA1c) and insulin resistance, and lower prevalence of diabetes and metabolic syndrome [17] , while chronic infection with this helminth was associated with lower serum triglycerides and total cholesterol [18] . Among Australian Aboriginals, Strongyloides stercoralis infection was associated with a lower likelihood of diabetes [19] and treatment of Strongyloides worsened glycaemic status [20] . Among the Tsimane of the Bolivian Amazon, helminth infection was inversely associated with serum lipid levels [21] . Chronic infection with the trematode Opisthorcis felineus was associated with lower serum cholesterol levels and diminished atherosclerosis in a post-mortem study in Russia [22] . In Indonesia, infection with soil-transmitted helminths (STH) was associated with lower insulin resistance and body mass index (BMI) [23] . The only trial to date, conducted in Indonesia, showed no effect of albendazole treatment for STH on insulin resistance, BMI or waist circumference overall, but increased insulin resistance in individuals infected with STH at baseline [24] .
Observational studies cannot demonstrate causality and are prone to bias from unmeasured confounders. The only previous trial was done in a setting with high prevalence of STH. However, other parasitic infections such as S. mansoni, may have a different impact on metabolic outcomes because of the different location of adult worms and inflammatory and regulatory elements of their life cycles. We therefore aimed to investigate, in a high S. mansoni prevalence setting, the effect of helminths and their treatment on metabolic outcomes in individuals aged 10 years. We also conducted observational analyses to assess cross-sectional associations between helminths and metabolic outcomes.
METHODS

Study setting and design
This was a two-arm cluster-randomised trial of community-wide intensive versus standard anthelminthic treatment conducted in 26 Lake Victoria fishing villages of Koome sub-county, Mukono district, Uganda (ISRCTN47196031). This population is ethnically diverse with the majority from central Uganda (of Bantu ethnic origin). There is some acculturation as different ethnic groups live together and use Luganda as the lingua franca. The main economic activity is fishing with a minority involved in agriculture. Villages are well defined, geographically separate and close to the lake. The residents live in temporary housing made from wood (locally obtained) and roofed with iron sheets or plastic. Houses are built close together. The island communities trade with mainland communities (both nearby and far) in fish and general merchandise.
The protocol has been published [25] . Briefly, 13 villages were randomised to intensive and 13 to standard intervention. Intensive treatment comprised praziquantel 40mg/kg single-dose administered using an extended height pole (which extended treatment to include pre-school age-groups) and albendazole 400mg triple-dose, both quarterly. Standard treatment comprised single-dose praziquantel (40mg/kg) annually and single-dose albendazole (400mg) bi-annually. Trial interventions started in September 2012. Originally, the trial was designed to investigate the effects of three years' intervention on allergy-related outcomes and helminth-related morbidity but interventions were extended for an extra year allowing us to assess their impact on metabolic outcomes.
Randomisation and masking
This was an open trial. Villages were randomised in a 1:1 ratio using restricted randomisation to ensure balance for village size, previous community-wide anthelminthic treatment and distance from the subcounty health centre [25] .
Exposures and outcomes
The exposures of interest were anthelminthic intervention (for the trial) and helminth infections (for observational analyses). The primary outcome was insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR) [26] , calculated as (fasting serum insulin (U/ml) x fasting glucose (mmol/L)) / 22.5. Secondary outcomes were fasting blood glucose, glycated haemoglobin (HbA1c), fasting serum lipids (triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol), blood pressure, body mass index (BMI), waist circumference and waist-hip ratio; and (for the trial) helminth infection status.
Procedures
The effects of helminths and anthelminthic intervention were assessed in a household survey conducted in all study villages after four years of intervention. We selected 70 households per village by simple random sampling using STATA (College Station Texas, US) (Supplementary methods). Permission for household participation was sought from each household head or another adult in the household if the head was absent. Household members aged ≥10 years were invited to participate.
After obtaining written informed consent from each household member (and assent from individuals aged 10-17 years), a questionnaire was administered. Data were collected on socio-demographic characteristics, diet, exercise, lifestyle, personal and family history of diabetes and hypertension.
Participants' blood pressure (BP), weight, height, waist and hip circumference were measured using standardised procedures (Supplementary methods). Peripheral venous blood was collected after an overnight fast for measurement of the primary and secondary outcomes (Supplementary methods).
Each participant was requested to provide one stool sample, from which duplicate slides were made and examined independently by two experienced technicians using the Kato Katz method. Stool real-time 
Statistical methods
For this survey, we planned to recruit 1950 participants (Supplementary methods). Statistical analyses were done using STATA v13; all analyses allowed for within-cluster correlations. The trial analysis was by intention-to-treat and measured cluster-level differences. For continuous outcomes, means were calculated for each village (cluster-specific means) and the mean of these within each study arm was used as a summary measure of the outcome in that study arm. T-tests were used to compare clusterspecific means between arms, with corresponding 95% confidence intervals computed. Continuous outcomes with skewed cluster-specific mean distributions were log-transformed before analysis and results back-transformed to give geometric mean ratios. For binary outcomes we calculated risk ratios by dividing the mean of the cluster-specific proportions in the intensive arm by that in the standard arm.
P-values were calculated from t-tests comparing cluster-specific proportions, and confidence intervals using a Taylor series approximation to estimate standard errors. For all outcomes, the effects of the intervention were additionally adjusted for age and sex using a two-stage approach [27].
The individual level observational analysis was performed to assess helminths as risk factors for metabolic disease. Potential confounders were identified based on a causal diagram (supplementary figure 1). Crude and adjusted associations were estimated using linear regression models fitted for each worm separately. Stata "svy" commands were used to allow for clustering of participants within villages, and for the non-self-weighting survey design due to variable village sizes. For adjusted analyses, only risk factors/ confounders crudely associated with the outcome with p-value≤0.15 were included in final models. No corrections were made for multiple testing. Characteristics of participants are shown in table 1. This is a young population with mean age 31.5 years (SD 11) considering that individuals <10 years were excluded. There are more males than females and the main occupation is fishing; the majority (69%;1309/1898) reported daily contact with the lake.
Ethical considerations
Activity levels were high: 48.4% (920/1898) reported vigorous physical activity at least weekly, with mean number of days 2.8 (SD 2.7). Diet mainly consists of fish (eaten on average 4.8 days a week) and is low in fruit (on average one day a week). The majority of participants (64.2%; 1218/1898) reported having lived in the village in which they were surveyed throughout the four-year intervention period. Participants living in intensive anthelminthic intervention villages had lower S. mansoni prevalence than those in standard intervention villages (stool Kato Katz, intensive 21.9%, standard 35.6%, p=0.02; stool PCR, intensive 37.3%, standard 56.0%, p=0.01). Similar effects were observed for hookworm (stool PCR, intensive 2.3%, standard 4.8%, p=0.03) and Strongyloides (stool PCR, intensive 4.8%, standard 9.0% p=0.02). Around half of S. mansoni infections were of light intensity (intensive 12.2%, standard 17.4%).
The intervention had no effect on Trichuris trichiura (table 2) .
There was no evidence of a difference in HOMA-IR between the study arms (table 3) . However, there was some evidence of a difference in mean LDL-cholesterol, higher in the intensive arm (2.86 versus 2.60mmol/l, adjusted mean difference [95% CI] 0.26 [-0.03,0.56] p=0.08). No differences were seen between trial arms for the other metabolic parameters (table 3) . Further analysis of the metabolic outcomes categorised as binary (diabetes, impaired fasting glucose, hypertension, obesity and metabolic syndrome) showed no differences between trial arms (supplementary table 1 helminth species was associated with lower total and LDL-cholesterol (trend p=0.02).
Four serious adverse events (SAEs) were reported in the first three years of the anthelminthic intervention [28]. In the fourth year of the intervention, no SAEs were reported.
DISCUSSION
This is the first trial to investigate effects of an anthelminthic intervention on metabolic outcomes in an S. mansoni endemic, high-transmission, setting. We found no effect of four years of intensive versus standard anthelminthic treatment on insulin resistance, but there a modest increase in LDL-cholesterol in the intensive versus standard arm. Consistent with this, there was strong observational evidence of association between S mansoni infection and lower levels of total cholesterol and LDL-cholesterol. The lowest levels of triglycerides and diastolic blood pressure were observed among participants with heavy S. mansoni infection and the lowest levels of LDL-cholesterol among those with moderate S. mansoni intensity. Strongyloides infection was also inversely associated with LDL-cholesterol. A dose-response relationship was observed between increasing numbers of helminth species detected and lower cholesterol levels.
The effect of the intervention on LDL-cholesterol and consistency of this with our cross-sectional observations strongly suggests a causal link between helminth infection and lipid profiles. Our results, in a setting dominated by schistosomiasis, accord with findings in experimental animals [14, 29] Arterial stiffness triggers angiotensin II which results in hypertension. Helminths may influence these pathways via their immunomodulatory properties. Helminths may also indirectly influence blood pressure through effects on the intestinal microbiome. Gut microbiota digest fibre and release short chain fatty acids which, on absorption into the circulation stimulate the release of renin, a major component of the renin angiotensin aldosterone system [38] . We recommend studies to further explore the relationship between helminth infection and BP.
We were surprised to find no impact of anthelminthic treatment or of helminths on insulin resistance, given the strong evidence of effects from animal models and evidence of increased insulin resistance following STH treatment among participants in the Indonesian trial. Perhaps the most probable explanation lies in the transmission dynamics of schistosomiasis in this transmission "hot-spot" setting;
and in the biology of schistosomes, as distinct from STH. In this trial, we observed a reduction in helminth prevalence in the standard arm over time, as well as in the intensive arm [25, 28] and this may have weakened any chance of seeing a differential effect of trial interventions on the metabolic outcomes. As well, single stool Kato Katz analysis has low sensitivity in detecting S. mansoni infection. As previously reported, the more sensitive urine circulating cathodic antigen (CCA) used after three years of intervention suggested persistent (albeit reduced intensity) infection in over 80% of participants in both trial arms, presumably due to on-going transmission and re-infection. Moreover, schistosomes differ from STH in that they reside in the vasculature and treatment does not result in immediate expulsion from the body. Immunological changes induced by helminths persist even after treatment of the worms. 
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